Trials
2 active
4 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “A tumor sample from individual participant is collected through a surgical resection for ex vivo manufacturing of GT201 TIL cell product.”In the company’s words, NCT07766317 on ClinicalTrials.gov
- Main trialPhase 1/2
- “This is a multicenter Phase I/II clinical trial. It aims to evaluate the safety, tolerability, efficacy and pharmacokinetics (PK) of GT201 in patients with advanced solid tumors.”In the company’s words, NCT06144671 on ClinicalTrials.gov
Other drugs for Advanced Solid Tumors
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up2
- 30 Dec 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Jun 2030Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 30 Dec 2027 | Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors | |
| Phase 1/2Not yet recruiting | Jun 2030 | Autologous Tumor Infiltrating Lymphocyte (TIL) GT201 Infusion. | |
| Phase 1/2Terminated | 30 Dec 2025 | Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors | |
| Phase 1Terminated | 30 Dec 2025 | Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/Recurrent Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026